Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC004968 | Panoply™ Human EPAS1 Knockdown Stable Cell Line | Inquiry |
| CSC-RK0274 | Human EPAS1 Knockdown Cell Line-HeLa | Inquiry |
| CSC-SC004968 | Panoply™ Human EPAS1 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT0596 | Human EPAS1 Knockout Cell Line-HeLa | Inquiry |
| CLKO-0101 | EPAS1 KO Cell Lysate-HeLa | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD05503Z | Human EPAS1 adenoviral particles | Inquiry |
| LV11795L | human EPAS1 (NM_001430) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH035201 | shRNA set against Rat Epas1(NM_023090.1) | Inquiry |
| SHH286169 | shRNA set against Human EPAS1 (NM_001430.4) | Inquiry |
| SHH286177 | shRNA set against Rat EPAS1 (NM_023090.1) | Inquiry |
| SHH286173 | shRNA set against Mouse EPAS1 (NM_010137.3) | Inquiry |
| SHW005313 | shRNA set against Chicken EPAS1 (NM_204807) | Inquiry |
| SHW009536 | shRNA set against Danio rerio EPAS1B (NM_001039806) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCR379270 | Rat Epas1 ORF Clone(NM_023090.1) | Inquiry |
| CDCS410272 | Human EPAS1 ORF Clone (BC051338) | Inquiry |
| CDFR012193 | Rat Epas1 cDNA Clone(NM_023090.1) | Inquiry |
| MiUTR1R-01746 | EPAS1 miRNA 3'UTR clone | Inquiry |
| MiUTR4H-TG03101 | EPAS1 miRNA 3'UTR clone | Inquiry |
| SKO0047 | EPAS1 Validated sgRNA vector | Inquiry |
| CDCB160205 | Human EPAS1 ORF clone (BC015869) | Inquiry |
| CDCB166788 | Chicken EPAS1 ORF Clone (NM_204807) | Inquiry |
| CDCB171011 | Danio rerio EPAS1B ORF Clone (NM_001039806) | Inquiry |
| CDCB188554 | Rabbit EPAS1 ORF clone (XM_008254453.1) | Inquiry |
| CDCR060594 | Mouse Epas1 ORF clone (NM_010137.3) | Inquiry |
| CDCS410271 | Human EPAS1 ORF Clone (BC015869) | Inquiry |
Endothelial PAS domain-containing protein 1 (EPAS1), also known as Hypoxia inducible factor 2 (HIF-2α). It is a major transcription factor for cells and tissues to respond to hypoxia and plays an important role in the changes of enzymes or factors caused by hypoxia. EPAS1 is expressed primarily in the placenta, heart, lung and endothelial cells. It induces expression in hypoxic regions and regulates the expression of genes necessary for tumor to adapt to hypoxic state, such as encoding VEGF, EPO, Glut and glycolytic enzyme, thus playing an important role in angiogenesis, bone marrow hematopoiesis, energy metabolism and tumor development. In the case of normoxia (21% O2), EPAS1 degrades. In the absence of oxygen (1% O2), EPAS1 promotes the expression of genes that mediate cellular responses to hypoxic conditions via the HIF complex.
Figure 1. Oxygen sensing by VHL complex. (M Janeš, et al. 2017)
EPAS1 Gene Polymorphism
The EPAS1 gene plays an important role in oxygen sensing and oxygen metabolism. Studies have found that mutations in the EPAS1 gene in the plain population can also lead to erythrocyte proliferation. Studies have shown that the EPAS1 gene polymorphism site plays a key role in regulating red blood cell (RBC) production and hemoglobin (Hb) concentration. The study found that the rs13419896 and rs1868092 mutations in the EPAS1 gene regulatory region were not only different between the Tibetan population and the Han population, but also correlated with Tibetan low Hb levels. Studies have shown that the A allele of rs6756667 locus of EPAS1 gene may be a favorable factor for plateau hypoxia adaptation in Tibetan population, and GG genotype may be an unfavorable factor for Tibetan athletes to adapt to plateau hypoxia. The EPAS1 gene plays a key role in the plateau hypoxia adaptation process in the Tibetan population.
EPAS1 and Tumor
EPAS1 is widely present in the human body under hypoxic conditions, and can promote the production of angiogenic factors such as vascular endothelial growth factor, thereby promoting tumor neovascularization, which leads to enhanced malignant behavior of tumor cells and anti-radiation therapy. EPAS1 is low or no expression in normal tissues, but can be expressed in a variety of tumor tissues or cells and regulate its biological behavior. Studies have shown that in endometrial carcinonma (EC), the expression of EPAS1 m RNA is increased, which is more than twice that of normal endometrial tissue. The expression of EPAS1 protein is significantly increased, which is 4 times that of normal endometrial tissue. Moreover, the later the EC staging, the deeper the infiltration depth, the higher the positive expression rate of EPAS1.
In a study by Raspaglio et al., it was found in the A2780 cell line that silencing of EPAS1 inhibited the proliferation of ovarian cancer (OC) cancer cells and increased the sensitivity of OC cancer cells to paclitaxel and cisplatin. The small interfering RNA (si RNA) experiment targeting EPAS1 by OC cell line showed that EPAS1 was inhibited at both mRNA level and protein expression level, and the growth curve of OC cells tended to be stable. This result showed that the malignant biological behavior of OC cells is effectively controlled. By analyzing the expression of EPAS1 in patients with OC, it was found that patients with low expression of EPAS1 gene had longer survival time and better prognosis.
References: